Discover More Light
Utilization with
Less Light Scatter1,2*
Clareon® PanOptix® Pro
*Compared to Clareon® PanOptix®, Based on bench and vision simulator studies.
Discover More Light Utilization with Less Light Scatter1,2*
Clareon® PanOptix® Pro
*Compared to Clareon® PanOptix®, Based on bench and vision simulator studies.
Everything You Love About Clareon® PanOptix® Now With Less Light Scatter1-3**
Unprecedented 94% Light Utilization4-10†
With ENLIGHTEN® NXT Optical Technology, PanOptix® Pro now offers:
- 50% less light scatter by harnessing 94% of total light energy1-3††
- The lowest light scatter of any trifocal IOL1-3,6,10‡,‡‡
- Uninterrupted light distribution across the full visual range1§
**PanOptix® has 88% light utilization (12% scatter light)/PanOptix® Pro 94% light utilization (6% scatter light).
†Compared to Clareon® PanOptix®.
††Compared to Clareon® PanOptix®. PanOptix® has 88% light utilization (12% scatter light)/PanOptix® Pro 94% light utilization (6% scatter light).
‡Based on bench and vision simulator studies.
‡‡Based on manufacturer reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner.
§Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic.
Designed For Better Image Contrast1†§
†Compared to Clareon® PanOptix®.
§Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic.
Minimize Visual Disturbances
Built on the clinically proven visual disturbance profile of world-leading PanOptix®
Starburst
Only 2.6% of patients were bothered very much by starburst11§§ (n=220)
Halo
Only 1.4% of patients were bothered very much by halo11§§ (n=222)
Glare
Only 0.8% of patients were bothered very much by glare11§§ (n=221)
§§Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including "very bothersome” and "severe" visual disturbances. Clinical studies were performed on the AcrySof® IQ PanOptix® IOL; AcrySof® IQ PanOptix® and Clareon® PanOptix® are optically equivalent.
Outstanding Spectacle Independence
- True comfort at intermediate distance12-17¶
- High quality near vision up to the very close distance of 33 cm12¶¶
- Freedom from glasses even in low light18#,##
¶AT LISA^ tri 839MP^, PhysIOL FineVision^ and Envista^ Envy.
¶¶Based on data for AcrySof® IQ PanOptix® Trifocal IOL. AcrySof® IQ PanOptix® and Clareon® PanOptix® are optically equivalent.
#All-implanted analysis set.
##In response to the IOLSAT questionnaire question “In the past 7 days, how often did you need to wear eyeglasses to see”?
^Trademarks are the property of their respective owners.
Undeniable Patient Satisfaction
- PanOptix® is a trusted choice
- 99.2% of PanOptix® patients would have the same lens implanted again19||,¶¶
- 98.4% of PanOptix® patients would recommend the lens to a friend19¶¶,***
¶¶Based on data for AcrySof® IQ PanOptix® Trifocal IOL. AcrySof® IQ PanOptix® and Clareon® PanOptix® are optically equivalent.
||Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127.
***Response to the following question on IOLSAT questionnaire at 6 months post-op "Given your vision today, would you recommend the lenses you had implanted to your family or friends?"; n=127.
Explore additional resources for Clareon® PanOptix® Pro IOLs
Are you ready to level up to the Power of Pro?†††
†††Compared to Clareon® PanOptix®, based on increased light utilization of 88% to 94%.
Available in AutonoMe®
IMPORTANT PRODUCT INFORMATION
CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.
INDICATIONS
The Clareon® PanOptix® Pro Trifocal IOLs include Clareon® PanOptix® Pro and Clareon® PanOptix® ProToric and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. In addition, the Clareon® PanOptix® Pro Toric Trifocal IOL is indicated for the reduction of residual refractive astigmatism.
WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centration is achieved.
For the Clareon® PanOptix® Pro Toric Trifocal IOLs, the lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation.
Some visual effects may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos, radial lines around point sources of light (starbursts) under nighttime conditions, or glare, as well as other visual symptoms. As with other multifocal IOLs, there is a possibility that visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. A reduction in contrast sensitivity as compared to that expected with a monofocal IOL may be experienced by some patients and may be more prevalent in low lighting conditions. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions.
Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning).
As with other multifocal IOLs, patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO), may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with the IOLs.
ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions.
References:
1. Alcon data on file, 2025. REF-25218.
2. Alcon data on file, 2024. REF-25221.
3. Alcon data on file, 2015. REF-08546.
4. Alcon data on file, 2025. REF-25218.
5. Alcon data on file, 2015. REF-08546.
6. Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston.
7. Rayner Professional Website. https://rayner.com/en/iol/trifocal/rayone-trifocal/. Accessed September 2024.
8. Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53.
9. ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014.
10. Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; https://europe.ophthalmologytimes.com/zeiss-cataract-insight-series?page=1 Accessed September 2024.
11. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.
12. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234.
13. Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614-1617. doi:10.1177/154193120805201965.
14. Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. https://www.ccohs.ca/oshanswers/ergonomics/office/.
15. Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164.
16. Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal.American Journal of Ophthalmology. 2016;161. doi:10.1016/j.ajo.2015.09.030.
17. Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/j.jcrs.0000000000000780.
18. Alcon data on file, 2018. REF-01475.
19. Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use.